{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:23:28Z","timestamp":1792517008235,"version":"4.5.0"},"reference-count":58,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Soluble human leucocyte antigen (sHLA) molecules, released into the plasma, carry their original peptide cargo and provide insight into the protein synthesis and degradation schemes of their source cells and tissues. Other body fluids, such as pleural effusions, may also contain sHLA-peptide complexes, and can potentially serve as a source of tumor antigens since these fluids are drained from the tumor microenvironment. We explored this possibility by developing a methodology for purifying and analyzing large pleural effusion sHLA class I peptidomes of patients with malignancies or benign diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cleared pleural fluids, cell pellets present in the pleural effusions, and the primary tumor cells cultured from cancer patients\u2019 effusions, were used for immunoaffinity purification of the HLA molecules. The recovered HLA peptides were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS\/MS) and the resulting LC-MS\/MS data were analyzed with the MaxQuant software tool. Selected tumor antigen peptides were tested for their immunogenicity potential with donor peripheral blood mononuclear cells (PBMCs) in an in vitro assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mass spectrometry analysis of the pleural effusions revealed 39,669 peptides attributable to 11,305 source proteins. The majority of peptides identified from the pleural effusions were defined as HLA ligands that fit the patients\u2019 HLA consensus sequence motifs. The membranal and soluble HLA peptidomes of each individual patient correlated to each other. Additionally, soluble HLA peptidomes from the same patient, obtained at different visits to the clinic, were highly similar. Compared with benign effusions, the soluble HLA peptidomes of malignant pleural effusions were larger and included HLA peptides derived from known tumor-associated antigens, including cancer\/testis antigens, lung-related proteins, and vascular endothelial growth factor pathway proteins. Selected tumor-associated antigens that were identified by the immunopeptidomics were able to successfully prime CD8<jats:sup>+<\/jats:sup> T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pleural effusions contain sHLA-peptide complexes, and the pleural effusion HLA peptidome of patients with malignant tumors can serve as a rich source of biomarkers for tumor diagnosis and potential candidates for personalized immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003733","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T13:42:33Z","timestamp":1653313353000},"page":"e003733","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens"],"prefix":"10.1136","volume":"10","author":[{"given":"Sofia","family":"Khazan-Kost","sequence":"first","affiliation":[{"name":"Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Cafri","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dganit","family":"Melamed Kadosh","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navit","family":"Mooshayef","sequence":"additional","affiliation":[{"name":"Institute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Chatterji","sequence":"additional","affiliation":[{"name":"Institute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Dominissini","sequence":"additional","affiliation":[{"name":"Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Manor","sequence":"additional","affiliation":[{"name":"Ezer Mizion Bone Marrow Donor Registry, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bracha","family":"Zisser","sequence":"additional","affiliation":[{"name":"Ezer Mizion Bone Marrow Donor Registry, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Broday","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrosiniia","family":"Talalai","sequence":"additional","affiliation":[{"name":"Institute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Shemer","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oranit","family":"Zadok","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Ofek","sequence":"additional","affiliation":[{"name":"Pathology Department, Chaim Sheba Medical Center, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Onn","sequence":"additional","affiliation":[{"name":"Institute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-3950","authenticated-orcid":false,"given":"Arie","family":"Admon","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Peled","sequence":"additional","affiliation":[{"name":"Institute of Pulmonary Medicine, Chaim Sheba Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"2025100312310609000_10.5.e003733.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"2025100312310609000_10.5.e003733.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183"},{"key":"2025100312310609000_10.5.e003733.3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4694"},{"key":"2025100312310609000_10.5.e003733.4","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.131"},{"key":"2025100312310609000_10.5.e003733.5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0526"},{"key":"2025100312310609000_10.5.e003733.6","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.836911"},{"key":"2025100312310609000_10.5.e003733.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.08.010"},{"key":"2025100312310609000_10.5.e003733.8","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700284","article-title":"Translating Immunopeptidomics to Immunotherapy-Decision-Making for patient and personalized target selection","volume":"18","author":"Fritsche","year":"2018","journal-title":"Proteomics"},{"key":"2025100312310609000_10.5.e003733.9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2025100312310609000_10.5.e003733.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.06.008"},{"key":"2025100312310609000_10.5.e003733.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008501107"},{"key":"2025100312310609000_10.5.e003733.12","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201500445"},{"key":"2025100312310609000_10.5.e003733.13","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA119.001524"},{"key":"2025100312310609000_10.5.e003733.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1403503"},{"key":"2025100312310609000_10.5.e003733.15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S2213-2600(19)30373-X","article-title":"Malignant pleural effusion management: keeping the flood gates shut","volume":"8","author":"Walker","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025100312310609000_10.5.e003733.16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1470-2045(18)30294-8","article-title":"Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (promise): a multicohort analysis","volume":"19","author":"Psallidas","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100312310609000_10.5.e003733.17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100312310609000_10.5.e003733.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0371-0"},{"key":"2025100312310609000_10.5.e003733.19","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(78)90296-9"},{"key":"2025100312310609000_10.5.e003733.20","doi-asserted-by":"publisher","DOI":"10.1021\/pr050385q"},{"key":"2025100312310609000_10.5.e003733.21","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA119.001876"},{"key":"2025100312310609000_10.5.e003733.22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1511"},{"key":"2025100312310609000_10.5.e003733.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893"},{"key":"2025100312310609000_10.5.e003733.24","doi-asserted-by":"crossref","first-page":"W458","DOI":"10.1093\/nar\/gkx248","article-title":"GibbsCluster: unsupervised clustering and alignment of peptide sequences","volume":"45","author":"Andreatta","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2025100312310609000_10.5.e003733.25","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2014.064"},{"key":"2025100312310609000_10.5.e003733.26","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.007138"},{"key":"2025100312310609000_10.5.e003733.27","doi-asserted-by":"publisher","DOI":"10.1038\/nm0996-1005"},{"key":"2025100312310609000_10.5.e003733.28","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.3892\/mmr.2015.4385","article-title":"Neuroepithelial transforming gene 1 functions as a potential prognostic marker for patients with non-small cell lung cancer","volume":"12","author":"Fang","year":"2015","journal-title":"Mol Med Rep"},{"key":"2025100312310609000_10.5.e003733.29","first-page":"2491","article-title":"Clinical significance and prognostic value of Vav1 expression in non-small cell lung cancer","volume":"5","author":"Qi","year":"2015","journal-title":"Am J Cancer Res"},{"key":"2025100312310609000_10.5.e003733.30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103213","article-title":"Quiescin sulfhydryl oxidase 1 (QSOX1) secreted by lung cancer cells promotes cancer metastasis","volume":"19","author":"Sung","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025100312310609000_10.5.e003733.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75625-1","article-title":"SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer","volume":"10","author":"Burgess","year":"2020","journal-title":"Sci Rep"},{"key":"2025100312310609000_10.5.e003733.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp010731"},{"key":"2025100312310609000_10.5.e003733.33","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/139.3.663"},{"key":"2025100312310609000_10.5.e003733.34","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1210-1248"},{"key":"2025100312310609000_10.5.e003733.35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10499"},{"key":"2025100312310609000_10.5.e003733.36","doi-asserted-by":"crossref","first-page":"92966","DOI":"10.18632\/oncotarget.21715","article-title":"Genome-Wide identification of cancer\/testis genes and their association with prognosis in a pan-cancer analysis","volume":"8","author":"da Silva","year":"2017","journal-title":"Oncotarget"},{"key":"2025100312310609000_10.5.e003733.37","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41388-018-0357-2","article-title":"Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development","volume":"37","author":"Bruggeman","year":"2018","journal-title":"Oncogene"},{"key":"2025100312310609000_10.5.e003733.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.86837","article-title":"Profiling cancer testis antigens in non\u2013small-cell lung cancer","volume":"1","author":"Djureinovic","year":"2016","journal-title":"JCI Insight"},{"key":"2025100312310609000_10.5.e003733.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100136","article-title":"Proteogenomic analysis unveils the HLA class I-Presented immunopeptidome in melanoma and EGFR-mutant lung adenocarcinoma","volume":"20","author":"Qi","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"2025100312310609000_10.5.e003733.40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp427"},{"key":"2025100312310609000_10.5.e003733.41","doi-asserted-by":"publisher","DOI":"10.1136\/thx.54.8.707"},{"key":"2025100312310609000_10.5.e003733.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.007"},{"key":"2025100312310609000_10.5.e003733.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(99)00186-X"},{"key":"2025100312310609000_10.5.e003733.44","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700259","article-title":"The role of mass spectrometry and Proteogenomics in the advancement of HLA epitope prediction","volume":"18","author":"Creech","year":"2018","journal-title":"Proteomics"},{"key":"2025100312310609000_10.5.e003733.45","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12936"},{"key":"2025100312310609000_10.5.e003733.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2008.01106.x"},{"key":"2025100312310609000_10.5.e003733.47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"2025100312310609000_10.5.e003733.48","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053402"},{"key":"2025100312310609000_10.5.e003733.49","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4051"},{"key":"2025100312310609000_10.5.e003733.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0828"},{"key":"2025100312310609000_10.5.e003733.51","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"2025100312310609000_10.5.e003733.52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semcancer.2018.08.006","article-title":"Cancer-Testis antigens: unique cancer stem cell biomarkers and targets for cancer therapy","volume":"53","author":"Gordeeva","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"2025100312310609000_10.5.e003733.53","doi-asserted-by":"crossref","first-page":"188558","DOI":"10.1016\/j.bbcan.2021.188558","article-title":"Oncogenic cancer\/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy","volume":"1876","author":"Yang","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2025100312310609000_10.5.e003733.54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2400"},{"key":"2025100312310609000_10.5.e003733.55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fcell.2020.00118","article-title":"Rac-GEF\/Rac signaling and metastatic dissemination in lung cancer","volume":"8","author":"Cooke","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025100312310609000_10.5.e003733.56","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201900224","article-title":"Liquid biopsy based single-cell transcriptome profiling characterizes heterogeneity of disseminated tumor cells from lung adenocarcinoma","volume":"20","author":"Dong","year":"2020","journal-title":"Proteomics"},{"key":"2025100312310609000_10.5.e003733.57","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1759-7714.13006","article-title":"Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling","volume":"10","author":"Guo","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025100312310609000_10.5.e003733.58","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jprot.2018.09.018","article-title":"Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma","volume":"192","author":"White","year":"2019","journal-title":"J Proteomics"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:31:15Z","timestamp":1759519875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":58,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jitc-2021-003733"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003733","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}